Guangdong Provincial Hospital of Traditional Chinese Medicine
Shanghai Chest Hospital
Tumor growth rate (TGR) signifies percentage change in tumor size per month (%/m). Electronic medical records were retrospectively reviewed for all histologically confirmed aNSCLC patients undergoing anti-PD-1/PD-L1 therapy at Sun Yat-Sen University Cancer Center (SYSUCC) between August 2016 and June 2018.
All response and outcome evaluation were determined as per RECIST 1.1 by two senior radiologists blinded to patients'information. Discrepancy was solved by consensus.
X-tile software was used to determine cut-off values that maximumly differentiate overall survival (OS). Log-rank tests and Cox regression models were performed for survival analysis. The predictive value of TGR for clinical outcomes in ICI-treated aNSCLC patients was validated in two external cohorts, recruited form Guangdong Province Traditional Chinese Medical Hospital and Shanghai Chest Hospital.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed aNSCLC patients
Having received anti-PD-1/PD-L1 therapy
Must have two consecutive computed tomography (CT) scans upon early treatment (from baseline to the first imaging evaluation)
You may not be if
Lacking available computed tomography (CT) evaluation at any of two time points-baseline and the first evaluation
Without measurable lesions at baseline CT scan
Having received local anticancer therapy during ICI treatment, for example, radiotherapy and radiofrequency ablation
